Surgical management of pancreatic cancer liver oligometastases

Rebekah Macfie; Yael Berger; Umut Sarpel; Spiros Hiotis; Benjamin Golas; Daniel Labow; Noah Cohen

doi:10.1016/j.critrevonc.2022.103654

Surgical management of pancreatic cancer liver oligometastases

Crit Rev Oncol Hematol. 2022 May:173:103654. doi: 10.1016/j.critrevonc.2022.103654. Epub 2022 Mar 14.

Authors

Rebekah Macfie¹, Yael Berger¹, Umut Sarpel¹, Spiros Hiotis¹, Benjamin Golas¹, Daniel Labow¹, Noah Cohen²

Affiliations

¹ The Mount Sinai Hospital, United States.
² The Mount Sinai Hospital, United States. Electronic address: noah.cohen@moutnsinai.org.

PMID: 35301097
DOI: 10.1016/j.critrevonc.2022.103654

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, which commonly metastasizes to the liver. The current standard of care for metastatic PDAC is systemic chemotherapy, however there are limited emerging data regarding surgical resection of pancreatic oligometastases in select patients. Here we review the literature addressing resection of PDAC liver oligometastases.

Keywords: Carcinoma; Liver; Pancreatic Ductal; Standard of Care.

Publication types

Review

MeSH terms

Carcinoma, Pancreatic Ductal* / surgery
Humans
Liver Neoplasms* / secondary
Liver Neoplasms* / surgery
Pancreatic Neoplasms* / drug therapy